Quality Control Analyst

Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month. Published: Oct 13 2026, 12:15 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The firm's Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks. * The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. * A higher dose recorded one disease flare-up, compared with 17 in the placebo group. * The findings were presented at the American Society for Bone and Mineral Research. Regeneron Pharmaceuticals (REGN) reported encouraging long-term results for its recently approved rare disease drug on Monday, with patients showing no new abnormal bone growth during an extended Phase 3 trial. REGN shares were up about 2.8% and heading for their best day in over a month. What did the trial show? Regeneron's Pasatru treats fibrodysplasia ossificans progressiva (FOP), an extremely rare condition in which muscles, tendons and other soft tissues gradually turn into bone. The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. Between weeks 56 and 84, patients taking Pasatru developed zero new abnormal bone lesions, compared with nine in the placebo group. The findings were presented at the American Society for Bone and Mineral Research (ASBMR). Regeneron plans new study for children. The FDA approved Pasatru in August, following earlier trial results showing at least a 90% reduction in new abnormal bone lesions after 56 weeks. European regulators are currently reviewing Pasatru. The drug works by blocking Activin A, a protein involved in abnormal bone formation. Regeneron plans to begin another Phase 3 study, Optima 2, involving children and adolescents later this year. REGN's pipeline includes cancer, eye disease treatments. Beyond Pasatru, Regeneron is expanding its broader drug pipeline, which includes treatments for cancer, eye diseases and inflammatory conditions. The biotech firm recently expanded its partnership with Sanofi (SNY) to develop four new long-acting antibody treatments for inflammatory diseases. Under the deal, Regeneron will receive $1 billion upfront and could earn an additional $7 billion if the treatments meet certain development, regulatory, and sales targets. The companies will share development costs and split future profits equally. The company reported about $17.8 billion in cash and marketable securities as of June 30. Separately, BofA raised its price target on Regeneron to $908 from $891 and kept a 'Buy' rating. This implies a 19% upside from current levels. Retail remains bullish on REGN. Despite the recent run, retail sentiment on Stocktwits surrounding REGN remained 'bullish' over the past 24 hours. The stock is down around 1.4% so far this year, underperforming the broader State Street SPDR S&P Biotech ETF's (XBI) roughly 25% gains. Also read: Microsoft Looks In-House To Power Its AI Ambitions - CEO Nadella Calls It 'Our Biggest Bet Yet On Our Own Silicon' For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Regeneron Pharmaceuticals said its drug Pasatru (garetosmab-grts) showed sustained results in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to grow in muscle and connective tissue. The 84-week data from the Phase 3 OPTIMA trial were presented at the American Society for Bone and Mineral Research annual meeting. From week 56 to week 84, patients on Pasatru had no new abnormal bone lesions, against nine for placebo. New flare-ups numbered one on the 10 mg/kg dose, 14 on the 3 mg/kg dose, and 17 on placebo. The trial enrolled 63 adults. Skin and soft tissue infections rose with dose but all resolved, and no patients stopped treatment because of them. The US Food and Drug Administration recently approved Pasatru. A trial in children and adolescents is planned to begin later this year.

TODAY: President Trump rallies in Syracuse. Commentary. If you are covering President Trump's rally in Syracuse today, please consider this statement from the Republican National Committee: "Kathy Hochul is the worst governor in America and wants to keep New York a high-tax, pro-crime, sanctuary state. New Yorkers are sick of it and fired up to welcome President Trump and Republicans like Bruce Blakeman who will fight for all New Yorkers by standing with law enforcement, lowering costs, and bringing back common sense." - RNC Spokesperson Kristen Cianci Background: President Trump And Republicans Delivered Historic Tax Cuts * The Working Families Tax Cuts saved each New Yorker an average $4,079 in taxes. * New York will see wages increase by up to $8,000 over the next four years. * The expanded SALT cap delivered $32.2 billion in tax savings. * 5% of New York workers benefit from no tax on tips. * Up to 62% of New York workers benefit from no tax on overtime. * 3.3 million seniors in New York benefit from no tax on Social Security. President Trump Is Delivering Major Investments Across New York * President Trump has secured $11.2 trillion in direct foreign investments that are fueling job growth, innovation, and opportunity. * Micron raised its planned U.S. investments to more than $250 billion through 2035 for its new semiconductor manufacturing plant in Clay, New York, fourteen miles from Syracuse. * Anheuser-Busch invested $9 million into its Baldwinsville, New York, brewery near Syracuse to increase production of its alcohol brands. * GlobalFoundries announced $16 billion in investment to increase domestic semiconductor production and advanced packaging capabilities, including at its Malta, New York facility. * IBM announced plans to invest $150 billion into the United States over the next five years, including into its manufacturing plant in Poughkeepsie, New York. * Regeneron invested $2 billion into a new drug manufacturing facility in Saratoga County, creating 1,000 new jobs. * Chobani announced a $1.2 billion investment in a new manufacturing facility in Rome, New York. Thanks To President Trump Violent Crime Has Fallen At Historic Rates * In 2026, in New York, murders fell by 48%, and New York City saw the fewest shootings and murders in recorded history. * Operation Tidal Wave 1.0 arrested two people in Albany, New York, during a fraud investigation that led to the seizure of over 130 illegal firearms. * Operation Tidal Wave 2.0 arrested over 40 people in Albany, New York, in connection with drug distribution and illegal firearms. * Francisco Javier Roman-Bardales, a high-ranking member of MS-13, was charged in the Eastern District of New York for narco-terrorism, racketeering, material support for terrorism, and alien-smuggling conspiracies. * Operation Rotten Apple arrested nearly 2,200 illegal aliens across New York, including murderers, rapists, pedophiles, drug traffickers, and violent criminals. * Operation Salvo arrested 54 people in an immigration enforcement surge in New York following the shooting of a CBP officer; among those arrested are members of transnational gangs responsible for drug and weapon trafficking and human smuggling.